Bruno Domon (Presenter)
Luxembourg Clinical Proteomics Center
Bio: Bruno Domon is an expert in biological mass spectrometry and proteomics, heading the Luxembourg Clinical Proteomics Center, at L.I.H., where he leads a program funded by the Fonds National de la Recherche (PEARL grant). His main focus is the development of novel mass spectrometry-based proteomics methodologies, and their application to biomarker discovery and evaluation. His current interest is in personalized medicine and personalized therapies and he is collaborating with the clinicians to develop new diagnostics tools in oncology. Previously, he was group leader and principal investigator at the Institute of Molecular Systems Biology at ETH in Zurich (2005-2009). As director at Celera Genomics in Rockville MD (2001-2004) he led the proteomics program, focused on the identification of cell surface proteins for oncology therapeutic development and diagnostics.
Authorship: Bruno Domon1, Lina Ancheva1, Sebastien Gallien1, Antoine Lesur1, Guy Berchem2
1Luxembourg Clinical Proteomics Center, Strassen, Luxembourg, 2 Laboratory of Experimental Hemato-Oncology, Strassen, Luxembourg
| Short Abstract Targeted proteomics analyses of biomarkers are routinely performed on triple quadrupole mass spectrometers, which present limited selectivity. The analyses of clinical samples performed on a quadrupole-orbitrap instrument using parallel reaction monitoring (PRM) showed a significant gain in sensitivity and selectivity. A new acquisition method leveraging the presence of internal standards showed a dramatic improvement of the reliability and the precision of the analyses. The method has a broad applicability to the quantitative analysis of clinical samples, such as lung cancer plasma samples to discriminate the disease stages and subtypes, and of tissue samples to map driver mutations (EGFR and KRAS). |
Long Abstract
Targeted proteomics analyses of biomarkers are routinely performed on triple quadrupole mass spectrometers in selected reaction monitoring (SRM) mode. However, the low resolution quadrupole mass filters present limited selectivity, especially for complex samples such as bodily fluids. Hybrid mass spectrometers with high resolution and accurate mass capabilities overcome this limitation, and have opened new avenues in quantitative proteomics. The targeted analyses of clinical samples carried out on a quadrupole-orbitrap mass spectrometer using parallel reaction monitoring (PRM) showed a significant gain in sensitivity and selectivity. The technique decouples the data acquisition from the data analysis and offers flexible experimental design as well as iterative data analysis.
The development of a new acquisition method leveraging the presence of internal standards has further improved the reliability and the precision of the analyses.
In order to fully leverage the potential of the PRM technique and to apply it to clinical assays, we have designed a new data acquisition scheme called internal standard triggered – parallel reaction monitoring (IS-PRM). This method relies on the addition of internal standards (i.e., isotopically labeled peptides) to adjust on-the-fly the acquisition parameters (resolution and fill time) to drive in real-time the measurement of endogenous peptides (corresponding to the proteins of interest). This generates precise and high confidence measurements as the acquisition time is managed to maximize the time effectively devoted to each analyte while keeping an appropriate cycle time. In the IS-PRM approach, the acquisition alternates between two modes: a fast low resolution “watch mode” and a “quantification mode” using optimized parameters ensuring high quality quantitative data. A redefined PRM workflow presenting specific characteristics was developed. First, the acquisition method contains limited information about the analytes (elution time and optimum precursor m/z); it also includes instrument parameters, which are adjusted according to the distribution of the peptide elution times and the intended trade-off between the scale of the experiment and the selectivity and sensitivity of measurements. Second, the data processing method defines an extended list of fragments to be used to assess peptide identity and to perform quantification. The same procedure was also applied to IS-PRM in order to set the acquisition parameters in real-time.
A complete informatics solution was developed to support the workflow, allowing a fully automated execution of PRM experiments. A module allows the creation of spectral libraries from the analysis of synthetic reference peptides (including meta-information such as their normalized elution time). It is also used to generate the acquisition methods by compiling the information for the targeted peptides specified in a query. It has specific options for the type of experiment (screening versus quantification), and the acquisition mode. The acquisition method is directly uploaded to the instrument controlling software. The data processing method, also based on the spectral library, indicates the fragments (primary and alternative, with their relative intensity) to be used for peptide identity confirmation and fragment qualification in actual analyses. A computational tool supports this iterative process and ultimately provides peptide qualified fragment ions whose traces are extracted. The relevant PRM traces output can be directly uploaded to Skyline to perform the actual quantification while reducing the volume of data. A proof-of-principle was performed in IS-PRM mode to quantify 600 endogenous peptides representing 338 proteins in bodily fluids. The developed method has a broad applicability and enables routine quantitative analyses. It was applied to the analysis of clinical samples, more specifically to lung cancer markers in plasma samples and, it allowed a clear discrimination of the disease stages and subtypes. The approach was also applied to map driver mutations (EGFR and KRAS) in lung cancer tissues samples, in order to assist the clinicians to select adequate treatments.
References & Acknowledgements:
| Description | Y/N | Source |
| Grants | no | |
| Salary | no | |
| Board Member | no | |
| Stock | no | |
| Expenses | no |
IP Royalty: no
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | no |